SCM
Sarissa Capital Management Portfolio holdings
AUM
$154M
This Quarter Return
+5.6%
1 Year Return
-6.05%
3 Year Return
-7.91%
5 Year Return
+32.47%
10 Year Return
+262.41%
AUM
$1B
AUM Growth
+$1B
(+28%)
Cap. Flow
+$191M
Cap. Flow
% of AUM
18.97%
Top 10 Holdings %
Top 10 Hldgs %
99.97%
Holding
12
New
1
Increased
3
Reduced
1
Closed
1
Top Buys
| 1 |
Alkermes
ALKS
|
$159M |
| 2 |
Neurocrine Biosciences
NBIX
|
$21.8M |
| 3 |
Innoviva
INVA
|
$8.44M |
| 4 |
Gilead Sciences
GILD
|
$5.43M |
Top Sells
| 1 |
Mersana Therapeutics
MRSN
|
$3.84M |
| 2 |
PEAR
Pear Therapeutics, Inc. Class A Common Stock
PEAR
|
$128K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alkermes
ALKS
$4.78B
| $439M | 43.75% | 14,040,000 +5,075,360 | +57% | +$159M |
|
2
Biogen
BIIB
$19.4B
| $183M | 18.23% | 643,000 | – | – |
|
3
Ironwood Pharmaceuticals
IRWD
$214M
| $174M | 17.36% | 16,390,000 | – | – |
|
|
4
Innoviva
INVA
$1.29B
| $92.6M | 9.22% | 7,277,000 +663,000 | +10% | +$8.44M |
|
|
5
Gilead Sciences
GILD
$140B
| $70.9M | 7.06% | 920,400 +70,400 | +8% | +$5.43M |
|
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $21.8M | 2.17% | +231,300 | New | +$21.8M |
|
|
7
Mersana Therapeutics
MRSN
$36.5M
| $8.66M | 0.86% | 2,632,900 -1,167,100 | -31% | -$3.84M |
|
|
AMRN
8
Amarin Corp
AMRN
$311M
| $5.84M | 0.58% | 4,910,000 | – | – |
|
9
BioCryst Pharmaceuticals
BCRX
$1.74B
| $5.46M | 0.54% | 775,000 | – | – |
|
10
Vor Biopharma
VOR
$250M
| $1.91M | 0.19% | 618,000 | – | – |
|
|
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
| $272K | 0.03% | 185,183 | – | – |
|
|
PEAR
12
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| – | – | -500,356 | Closed | -$128K |
|